Phosphoramide compounds

Details Phosphoramide compounds Phosphoramide compounds

2002-01-14

2003-12-02

McKane, Joseph K. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Phosphorus containing other than solely as part of an...

C548S414000

Reexamination Certificate

active

06656926

ABSTRACT:

BACKGROUND OF THE INVENTION
Increased selectivity of anti-cancer agents is an important factor in designing new drugs for the treatment of cancer. The design and synthesis of novel compounds that can be activated selectively in cancer cells is therefore an attractive way to target the inhibition of tumor growth. This strategy ensures that cytotoxicity occurs selectively in malignant cells and might lead to a reduction of many of the side effects commonly caused by chemotherapeutic agents currently in use. An approach to the enhancement of selectivity for cytotoxic chemotherapy involves the design of prodrugs that undergo preferential activation by enzymes that are overexpressed in tumors. These prodrugs, which are not cytotoxic until they are metabolically activated, can serve to deliver selectively the cytotoxic agent to the tumor site.
One such prodrug that is used clinically is the compound cyclophosphamide (1, FIG.
1
). Cyclophosphamide is activated to 4-hydroxycyclophosphamide (1a) by hepatic cytochrome P 450 oxidation (FIG.
1
). Subsequent &bgr;-elimination from the aldehyde tautomer of 1a releases phosphoramide mustard 2 as the active drug which can cyclize intramolecularly to a short-lived electrophilic aziridinium ion intermediate (3). Nucleophilic addition can then occur and the cyclization/addition process can be repeated. Ultimately, if DNA is the nucleophile, the phosphoramide mustard can cross-link DNA and inhibit further DNA replication, a process that leads to cell death.
The design of chemotherapeutic quinone prodrugs that are bioreductively activated by the enzyme DT-diaphorase has also been investigated (see for example P. Workman,
Oncol. Res.,
1994, 6, 461-475; and R. J. Riley and P. Workman,
Biochem. Pharmacol.,
1992, 43, 1657-1669). Many of the compounds studied include benzimidazolequinone, benzoquinone and naphthoquinone prodrugs, with and without an alkylating moiety attached to the core ring structure, and indolequinone analogs patterned after the known cytotoxic agents Mitomycin C and E09. Sartorelli et al prepared a series of naphthoquinone prodrugs that could potentially be transformed into alkylating moieties following the expulsion of a leaving group from the bioreductively activated compound (see for example, N. E. Sladek,
Pharmac. Ther.,
1988, 37, 301-355; and M. Colvin et al.,
Cancer Res.,
1976, 36, 1121-1126).
Despite the reported success in treating cancer with the compound Cyclophosphamide, there is currently a need for structurally novel therapeutic agents that can be used to treat cancer.
SUMMARY OF THE INVENTION
Applicant has discovered a series of novel compounds that possess useful cytotoxic properties when administered in vivo. Accordingly, the invention provides a compound of formula I:
wherein:
R
1
is an organic releasing group comprising a quinone ring;
R
a
, R
b
, R
c
, and R
d
are each independently hydrogen, (C
1
-C
6
)alkyl, or —CH
2
CH
2
X; and
each X is independently halo, (C
1
-C
6
)alkylsulfonyl, halo(C
1
-C
6
)alkylsulfonyl, or arylsulfonyl, wherein each aryl is optionally substituted with one or more (e.g. 1, 2, 3, or 4) halo, (C
1
-C
6
)alkyl, halo(C
1
-C
6
)alkyl, (C
1
-C
6
)alkoxy; (C
1
-C
6
)alkanoyl, (C
1
-C
6
)alkanoyloxy, (C
1
-C
6
)alkoxycarbonyl, cyano, nitro, or trifluoromethoxy;
provided at least two of R
a
, R
b
, R
c
, and R
d
are —CH
2
CH
2
X;
or a pharmaceutically acceptable salt thereof.
The invention also provides a pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable diluent or carrier.
Additionally, the invention provides a therapeutic method for preventing or treating cancer (e.g. a tumor) comprising administering to a mammal in need of such therapy, an effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof.
The invention also provides a compound of formula I for use in medical therapy (preferably for use in treating cancer, such as a tumor) as well as the use of a compound of formula I for the manufacture of a medicament for the treatment of cancer (e.g. a tumor) in a mammal, such as a human.
The invention also provides processes and intermediates useful for preparing compounds of formula I, or salts thereof.


REFERENCES:
patent: 5472956 (1995-12-01), Borch et al.
patent: 89/11484 (1989-11-01), None
patent: 90/10636 (1990-09-01), None
patent: 96/33198 (1996-10-01), None
Fladder; C., et al., “Development of Novel Quinone Phosphorodiamidate Prodrugs Targeted to DT-Diaphorase”,J. Med. Chem., vol. 43, No. 16,3157-3167, (Aug. 10, 2000).
Workman, P., “Enzyme-Directed Bioreductive Drug Development Revisited: A commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolizing enzymes, particularly DT-diaphorase”,Oncol. Res., vol. 6, XP000946783,461-475, (1994).

Affiliated with

Also associated with

Rating

Phosphoramide compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Phosphoramide compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Phosphoramide compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3112611